EQS-News: Carl Zeiss Meditec achieves further strong revenue growth after nine months of fiscal year 2022/23 with continued high strategic investments

EQS

Im Artikel erwähnte Wertpapiere: Carl Zeiss Meditec

EQS-News: Carl Zeiss Meditec AG / Key word(s): 9 Month figures/Quarterly / Interim Statement
Carl Zeiss Meditec achieves further strong revenue growth after nine months of fiscal year 2022/23 with continued high strategic investments

04.08.2023 / 07:00 CET/CEST
The issuer is solely responsible for the content of this announcement.


Carl Zeiss Meditec achieves further strong revenue growth after nine months of fiscal year 2022/23 with continued high strategic investments

JENA, 4 August 2023

Carl Zeiss Meditec generated revenue of around €1,509.6m in the first nine months of fiscal year 2022/23 (prior year: €1,332.9m) - growth of +13.3% (adjusted for currency effects: +12.9%). Earnings before interest and tax (EBIT) declined to around €244.9m (prior year: €275.9m). The EBIT margin was 16.2% (prior year: 20.7%).

“In the third quarter of 2022/23 we made further progress in stabilizing our supply chains and accelerated equipment deliveries, in spite of the delivery times of many products still being too long. Our innovation pipeline and targeted growth initiatives in sales and marketing are making steady progress,” says Dr. Markus Weber, President and CEO of Carl Zeiss Meditec AG.

Both strategic business units contributed to revenue growth

Revenue in the strategic business unit (SBU) Ophthalmology increased by +12.2% after nine months of the fiscal year (adjusted for currency effects: +11.8%), to €1,152.3m (prior year: €1,027.2m). Supply chains gradually stabilized over the course of the reporting period, allowing the delivery of equipment to progress well.

The strategic business unit Microsurgery achieved revenue growth of +16.9% (adjusted for currency effects: +16.5%), from €305.7m in the prior year to €357.3m. The strained supply chains gradually stabilized over the course of the reporting period, thus further accelerating the delivery of equipment recently. The order backlog remained high.

Growth in all reporting regions

Revenue in the EMEA[1]region increased by +11.4% (adjusted for currency effects: +13.0%) to €372.3m (prior year: €334.2m). France and Southern Europe, among others, made good contributions to growth.

Revenue in the Americas region increased by a significant +24.2% (adjusted for currency effects: +19.5%), from €330.4m to €410.3m. The order backlog in the U.S. market was reduced, particularly in the diagnostics business; surgical microscopes also developed well.

Revenue in the APAC[2]region developed at a constant level compared with the strong year-ago period, increasing by 8.8% (adjusted for currency effects: +9.5%) to €727.0m (prior year: €668.3m). While India and Southeast Asia, especially, made good contributions to growth, the Japanese and South Korean markets showed a slight downturn. The Chinese market, however, increasingly recovered over the course of the third quarter after the weak start to the year due to the pandemic.

Slight sequential recovery of EBIT and the EBIT margin in Q3 2022/23

Although the operating result (earnings before interest and taxes: EBIT) remained behind the prior-year level after the first nine months of fiscal year 2022/23, at €244.9m (prior year: €275.9m), a sequential recovery was achieved in the third quarter of fiscal year 2022/23 compared with the first six months of fiscal year 2022/23. The downward trend is due, among other things, to an unfavorable product mix. The continued long delivery times for refractive laser systems are currently preventing more dynamic growth of related consumables. At the same time, the planned strategic investments in research and development, including those in the area of digitization, and sales and marketing had an adverse effect. In addition, long lead times in a number of device categories also mean that the effect of price adjustments introduced to offset inflation has been delayed.

The EBIT margin was 16.2% after the third quarter (prior year: 20.7%). Adjusted for special effects, it was 16.8% (prior year: 21.2%). Earnings per share benefited from gains on currency hedges and increased to €2.29 year on year (prior year: €2.14).

Outlook for the further course of business in 2022/23

Revenue is expected to amount to around €2.1 billion in fiscal year 2022/23, corresponding to growth of approximately 10% compared with the prior year. The strategic investments in sales & marketing and research& development shall continue at a high level in the short to medium term. In spite of the gradual stabilization of the supply chains, the delivery times for key products remain long.

As explained in the 2021/22 Annual Report, stocks of consumables for refractive laser surgery were significantly increased in the Chinese distribution channel as a one-off strategic measure in the second half of fiscal year 2021/22, in order to ensure security of supply in the event of renewed regional COVID-19 lockdowns. These additional stocks are to be largely reduced at the beginning of fiscal year 2023/24, according to current Company planning. This planned stock reduction shall have a significant temporary impact on revenue and earnings in the first six months of fiscal year 2023/24. A small portion of the stock reduction is expected to take place in the fourth quarter of fiscal year 2022/23, which has already begun. Overall, the one-off negative effect of the stock reduction on revenue and EBIT is expected to be in the mid-double-digit million range.

The EBIT margin for fiscal year 2022/23 is expected to be at the lower end of the forecast range of 17 – 20%. In the medium term, the EBIT margin is expected to stabilize and return to the level of 20%. However, the duration of this recovery is currently not precisely predictable and will be determined to a large extent by the timing and amount of strategic investments in Research & Development and Sales & Marketing.

Revenue by strategic business unit

All figures in €m 9 Months
2022/23
9 Months
2021/22
Change from prior year % Change from prior year % (currency-adjusted)
Ophthalmology 1,152.3 1,027.2 +12.2 +11.8
Microsurgery 357.3 305.7 +16.9 +16.5
Consolidated 1,509.6 1,332.9 +13.3 +12.9

 

Revenue by region

All figures in €m 9 Months
2022/23
9 Months
2021/22
Change from prior year % Change from prior year % (currency-adjusted)
EMEA 372.3 334.2 +11.4 +13.0
Americas 410.3 330.4 +24.2 +19.5
APAC 727.0 668.3 +8.8 +9.5
Consolidated 1,509.6 1,332.9 +13.3 +12.9

 

Further information on our publication and the Analyst Conference Call on the results for the first nine months of fiscal year 2022/23 can be found at

https://www.zeiss.com/meditec-ag/investor-relations/financial-calendar/conference-calls.html

 

Contact for investors and press

Sebastian Frericks

Head of Group Finance & Investor Relations, Carl Zeiss Meditec AG

Phone: + 49 (0)3641 220-116

Email: investors.meditec@zeiss.com
 

www.zeiss.com/press

 

 

[1] Europe/Middle East/Africa

[2] Asia/Pacific



04.08.2023 CET/CEST Dissemination of a Corporate News, transmitted by EQS News - a service of EQS Group AG.
The issuer is solely responsible for the content of this announcement.

The EQS Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.
Archive at www.eqs-news.com


Language: English
Company: Carl Zeiss Meditec AG
Göschwitzer Str. 51-52
07745 Jena, Germany
Germany
Phone: +49 (0)3641 220-0
Fax: +49 (0)3641 220-112
E-mail: investors.meditec@zeiss.com
Internet: www.zeiss.de/meditec-ag/ir
ISIN: DE0005313704
WKN: 531370
Indices: MDAX, TecDAX
Listed: Regulated Market in Frankfurt (Prime Standard); Regulated Unofficial Market in Berlin, Dusseldorf, Hamburg, Hanover, Munich, Stuttgart, Tradegate Exchange
EQS News ID: 1695865

 
End of News EQS News Service

1695865  04.08.2023 CET/CEST

Im Artikel erwähnte Wertpapiere

Carl Zeiss Meditec 111,15 -1,51%
close

Populäre Aktien